8:25 am Chair’s Opening Remarks
Assessing Latest Breakthroughs From the Last 6 Months in NASH Reversal & Dual & Tri-Agonists for Weight Loss
8:30 am Illuminating the Breakthrough Therapy Designation for Resmetirom & Outlining the Safety & Efficacy Results for Treating NASH
Synopsis
- Leveraging the learnings of a multicentre, randomized, double-blind, placebo-controlled Phase 3 study
- How were non-invasive measures used?
- Comprehending the primary and secondary efficacy endpoints used to characterize the potential clinical benefits on cardiovascular endpoints
9:00 am CagriSemi for Weight Management – From Discovery to the Clinic
Synopsis
- CagriSema combines the actions of semaglutide and cagrilintide to improve several aspects of metabolism
- CagriSema displays dual efficacy of robust glycaemic control and body weight loss
- Weight loss of a higher magnitude contributes to additional glycaemic control and may have potential disease modifying effects
9:30 am Targeting GLP-1R & GIPR in a Novel Biospecific Mechanism to Advance a Longer-Acting Therapy for Weight-Loss
Synopsis
- Synergistic effects on weight loss and metabolic parameters in preclinical obese models
- Balancing durability, efficacy and safety to attain significant reduction in body weight
- Demonstrating competitive advantage with a first-in-class mechanism in Phase 1 and beyond and advancing a Phase 2 dose-ranging trials to demonstrate significant and durable weight loss
10:00 am Enzymatic Clearance of Excess Free Cholesterol Reduces NASH Pathology in Models of Disease
Synopsis
- Excess intracellular free cholesterol is hypothesized to drive NASH pathology
- Developing a LNP-mRNA therapy that expresses a cholesterol-degrading fusion protein in the liver
- 4 to 8 weeks of weekly dosing with the Repair Biotechnologies therapy significantly reduces NASH associated biomarkers and histology in mouse models of disease
10:30 am Speed Networking & Morning Break
Synopsis
Keen to shake hands and introduce yourself to the biggest minds working in the obesity & NASH? This is your opportunity to boost your contact list and establish purposeful business relationships.
Track A: Preclinical & Translational Track
Better Recapitulating NASH & Obesity in Preclinical Models to Improve Translational Success
Track Moderator:
Track Moderator:
11:30 am Three-Dimensional Primary Cell Based Liver Models Accurately Predict Clinical Outcomes of NASH Compared to Animal Models
Synopsis
- Moving away from 2D models and paving the way towards translational sucess with 3D cell-based models
- Accurately predicting clinical sucess and failure with novel 3D human cell-based models
- Revealing a physiologically relevant platform for NASH drug discovery efforts
12:00 pm A Once Daily Oral GLP-1R Full Agonist RGT-028 Improves Metabolic Profiles in Obese & Diabetic Cynomolgus Monkeys
Synopsis
- Suppressing food intake, improving glucose tolerance and lipid profiles
- Demonstrating superior pharmacological profile and favorable therapeutic index with approved IND
- Strategizing combination therapies for NASH
12:30 pm Evaluation of FASN inhibitor & GLP-1 Combination in Preclinical NASH Model
Synopsis
- Evaluating the fatty acid synthase (FASN) inhibitor and GLP-1 combination
- Assessing the anti-fibrotic efficacy by AI digital pathology
- Understanding MOAs of combination by transcriptomics
Track B: Clinical, Regulatory & Outcomes Track
Exploring the Next Generation of Combination Therapies & Assessing Their Safety in Clinical Trials
Track Moderators:
Track Moderators:
11:30 am Moving Beyond GLP1: Disentangling a FGF21 & GLP-1 Combination Therapy
Synopsis
- Discussing the synergies between the different mechanisms of action to target NASH
- Outlining the current trial design
- Unravelling the challenges and opportunities of moving into further development
12:00 pm Markers of the Extracellular Matrix May be Used to Understand Patient Endotyping & Therapeutical Effects in Patients with Steatotic Liver Disease
Synopsis
- The extracellular matrix (ECM) plays a crucial role in liver fibrosis, making neoepitope markers valuable for understanding patient endotypes
- Neoepitope markers of the ECM may be used as potential non-invasive test to displaying pharmacodynamic effects
- The monitoring of the ECM remodelling may can contribute help understanding disease progression in SLD
12:30 pm Disentangling Cutting-Edge Insights in Combination Therapy for Obesity & NASH Treatment
Synopsis
- Combination of GLP-1 and other mechanism has potential to lead to better therapeutic profile
- GIP, Amylin and GDF15 demonstrated synergy with GLP-1R agonist
- Unravelling novel considerations for designing combination studies
1:00 pm Lunch Break & Networking
2:00 pm Harnessing Gene Therapy for Prevalent Metabolic Indications
Synopsis
- Novel preclinical animal models to assess metabolic dysfunction
- Unravelling a class of new targets to optimize treatment of NASH and obesity
- Detailing the newest data and next steps forward
2:30 pm Panel Discussion: Deliberating the Benefits & Challenges of Current Preclinical Models to Move Towards Translational Success
Synopsis
- Increasing the relevance and accessibility of animal models to ease and shorten the drug discovery process
- How are rats and mice used to replicate NASH?
- Assessing the ability to recapitulate more than one aspect of disease
3:00 pm Chair’s Closing Remarks
2:00 pm SRT-015: A Second-Generation ASK1 Inhibitor for Liver Diseases Including NASH
Synopsis
- SRT-015 treatment results in direct inhibition of apoptosis, inflammation and fibrosis in vitro and in vivo
- Liver-selective small molecule efficacious in a chronic, therapeutic DIO-NASH preclinical model and in multiple acute liver models
- Demonstrated safety in Phase 1 clinical trials; ideal single or combination therapy
2:30 pm Panel Discussion: Navigating the Evolving NASH Landscape to Apprehend the Future of Combination Therapies & Optimize Treatment
Synopsis
- Deliberating the best approaches to position GLP-1s for different indications, mono therapy, and combination therapy
- How are we maximizing the use of injectables and oral medicines?
- Uniting towards a shared goal to advances towards efficacious NASH treatments through collaborative efforts
3:00 pm Chair’s Closing Remarks
3:10 pm Scientific Poster Session
Synopsis
This Poster Session is your go-to session to obtain competitive insights, deeply connect with your peers and present your most innovative work. Scientific posters will be presented on the most cutting-edge discovery efforts and clinical development for obesity & NASH that have the potential to drive the field forward.
For more information or to submit your abstract, please email info@hansonwade.com